Kalaris Therapeutics Inc (KLRS) Financials

KLRS Assets vs Liabilities
DateAssetsLiabilities
March 31, 2026 109.8 million 41.2 million
Dec. 31, 2025 121.7 million 42.9 million
Sept. 30, 2025 81.2 million 39.3 million
June 30, 2025 92.8 million 39.7 million

KLRS Free Cash Flow and Stock based compensation
Graph available only for paid members. Upgrade to see it.
DateFree Cash FlowStock based compensation
March 31, 2026 -13.4 million 580000
Dec. 31, 2025 -9.3 million 333000
Sept. 30, 2025 -11.5 million 638000
June 30, 2025 -14.9 million 591000

KLRS Net Income

No data available :(

KLRS Cash and Debt
Graph available only for paid members. Upgrade to see it.
DateCashDebtCapital Lease
March 31, 2026 97.2 million - 1.1 million
Dec. 31, 2025 118.0 million - 1.1 million
Sept. 30, 2025 77.0 million - 1.5 million
June 30, 2025 88.4 million - -

KLRS Shares Outstanding
Graph available only for paid members. Upgrade to see it.
DateShares Outstanding
March 31, 2026 23.7 million
Dec. 31, 2025 22.9 million
Sept. 30, 2025 18.7 million
June 30, 2025 18.7 million

KLRS Expenses
Graph available only for paid members. Upgrade to see it.
DateCapexR&DG&AS&M
March 31, 2026 - 7.6 million 4.3 million -
Dec. 31, 2025 17000 7.2 million 3.6 million -
Sept. 30, 2025 183000 9.1 million 3.6 million -
June 30, 2025 - 8.4 million 3.8 million -

KLRS Cost of Revenue
Graph available only for paid members. Upgrade to see it.
DateRevenueCost of Revenue
March 31, 2026 - 10000
Dec. 31, 2025 - 10000
Sept. 30, 2025 - -
June 30, 2025 - -

KLRS

Price: $4.72

52 week price:
2.14
11.88

Earnings Per Share: -0.79 USD

Exchange: NGM

Sector: Healthcare

Industry: Biotechnology

Market Capitalization: 87.0 million

Links: